Baird Medical to Participate in NASIT 2025 Conference

Rhea-AI Summary

Baird Medical Investment Holdings (NASDAQ: BDMD) has announced its participation in the 2025 North American Society for Interventional Thyroidology (NASIT) Conference, scheduled for January 31 – February 1, 2025, in Washington, D.C. The company, known for its leadership in Minimally Invasive Microwave Ablation (MWA) technology, will return to this premier thyroid interventions forum.

During the conference, Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, will present at the Product Theater, following his achievement of completing 100 MWA cases. The event provides Baird Medical with opportunities to engage with global experts, industry leaders, and potential partners while contributing to discussions on MWA technology advancements.

The company aims to gain insights into industry trends, optimize strategic initiatives, and continue driving innovation in global healthcare through this participation.

News Market Reaction

-5.64%

1 alert

-5.64% News Effect

On the day this news was published, BDMD declined 5.64%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leader in minimally invasive Microwave Ablation (MWA) technology, is pleased to announce its participation in the 2025 North American Society for Interventional Thyroidology (NASIT) Conference, taking place January 31 – February 1, 2025, in Washington, D.C.

The NASIT Conference is a premier forum for education, research, and collaboration in thyroid interventions, and Baird Medical is honored to participate in this key industry event. The Company's invitation highlights its growing prominence in the field of microwave ablation while offering a valuable opportunity to engage with global experts, industry leaders, and potential partners.

As a returning participant, Baird Medical is excited to contribute to discussions on the latest advancements in MWA technology and to collaborate with leading experts in interventional thyroidology. The Company also sees this as an opportunity to gain deeper insights into industry trends, optimize its strategic initiatives, and continue driving innovation and growth in global healthcare.

During the conference, Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, will present at the Product Theater, building on his recent milestone of completing 100 MWA cases. His session will provide insights into clinical experiences with MWA in thyroid care.

Baird Medical remains committed to supporting the ongoing advancement of minimally invasive technologies and collaborating with healthcare professionals to explore innovative approaches in thyroid treatment.

About Baird Medical

Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/

About NASIT

The North American Society for Interventional Thyroidology (NASIT) is the largest multidisciplinary group in the United States dedicated to the field of interventional thyroidology. The society was established to promote the safe integration of ablative thyroid technologies into clinical practice while fostering a collaborative environment that supports education and research in the field. NASIT's mission is twofold: (1) to ensure the safe adoption of ablative technologies in thyroid treatment and (2) to encourage interdisciplinary cooperation among physicians specializing in interventional thyroidology.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.

These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.

Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-to-participate-in-nasit-2025-conference-302359444.html

SOURCE BDMD

FAQ

When and where is Baird Medical (BDMD) participating in the NASIT 2025 Conference?

Baird Medical will participate in the NASIT Conference from January 31 to February 1, 2025, in Washington, D.C.

What will Dr. Kandil present at the NASIT 2025 Conference regarding BDMD's technology?

Dr. Emad Kandil will present at the Product Theater, sharing insights from his clinical experiences with MWA in thyroid care, following his milestone of completing 100 MWA cases.

What is the significance of BDMD's participation in the NASIT 2025 Conference?

The participation highlights Baird Medical's growing prominence in microwave ablation and provides opportunities to engage with experts, industry leaders, and potential partners while gaining insights into industry trends.

How many MWA cases has Dr. Kandil completed before the NASIT 2025 Conference?

Dr. Emad Kandil has completed 100 Microwave Ablation (MWA) cases prior to the NASIT 2025 Conference.

What technology is BDMD showcasing at the NASIT 2025 Conference?

Baird Medical will showcase its Minimally Invasive Microwave Ablation (MWA) technology, which is used in thyroid interventions.